Место фозиноприла в терапии сердечно-сосудистых заболеваний


Л.О. Минушкина

Место фозиноприла в терапии
сердечно-сосудистых заболеваний
В обзоре представлены убедительные, полученные в многоцентровых рандомизированных исследованиях доказательства эффективности и хорошей переносимости фозиноприла при артериальной гипертонии, нефропатии, сердечной недостаточности. По уровню гипотензивного эффекта фозиноприл не уступает другим ингибиторам ангиотензинпревращающего фермента, тиазидным диуретикам и антагонистам кальция. Препарат оказывает протективное влияние в отношении органов-мишеней у больных артериальной гипертензией, обладает антиатеросклеротическим действием, обеспечивает профилактику развития сердечной недостаточности после перенесенного инфаркта миокарда. Преимуществом фозиноприла перед другими ингибиторами АПФ является двойной путь элиминации, что обеспечивает возможность его применения у пациентов с нарушением функции почек.

Литература






  1. Li JS, Berezny K, Kilaru R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension 2004; 44(3):289–93.


  2. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996;9(7):633–43.


  3. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 2000;49(1):23–31.


  4. Anderson RJ, Duchin KL, Gore RD, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991;17(5):636–42.


  5. Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther 1990;12(6):520–33.


  6. Yesilbursa D, Serdar A, Ilcol B, et al. Effects of fosinopril treatment on blood pressure during physical and mental stress test in essential hypertension. Blood Press 1999;8(5–6):269–72.


  7. Fortini A, Cappelletti C, Cecchi L, et al. Fosinopril in the treatment of hypertension: effects on 24h ambulatory blood pressure and on blood pressure response to exercise. J Hum Hypertens 1994;8(6):469–74.


  8. Fernandez M, Madero R, Gonzalez D, et al. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension 1994;23(Suppl. 1):I207–10.


  9. Hansson L, Forslund T, Hoglund C, et al. Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients. J Cardiovasc Pharmacol 1996;28(1):1–5.


  10. Leonetti G, Trimarco B, Collatina S, et al. An effective approach for treating elderly patients with isolated systolic hypertension: results of an Italian multicenter study with fosinopril. Am J Hypertens 1997;10(10 Pt 2):230S–235S.


  11. Vetter W. Treatment of senile hypertension: the Fosinopril in Old Patients Study (FOPS). Am J Hypertens 1997;10(10 Pt 2):255S–261S.


  12. Карпов Ю.А. Фозиноприл при лечении артериальной гипертонии (ФЛАГ): российская программа оценки практической достижимости целевых уровней артериального давления // РМЖ. 2001. № 10. № 3–7.


  13. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25(5): 1034–41.


  14. Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study. Cardiovasc Drugs Ther 1995;9(1):141–3.


  15. Bilge AK, Atilgan D, Tukek T, et al. Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int J Clin Pract 2005;59(3): 306–10.


  16. Holdaway IM, Gamble GD, Sanders GA, et al. Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM. Diabetes Care 1994;17(12):1476–9.


  17. Hoffmann U, Globits S, Stefenelli T, et al. The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: a cine MRI study. J Magn Reson Imaging 2001;14(1):16–22.


  18. Chang NC, Shih CM, Bi WF, et al. Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovasc Drugs Ther 2002;16(2):141–7.


  19. Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial. Stroke 2004;35(12):2807–12.


  20. Alli C, Lombardo M, Zanni D, et al. Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Am J Hypertens 1996;9(11):1068–76.


  21. Fogari R, Preti P, Zoppi A. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15(12):1042–9.


  22. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21(4):597–603.


  23. Carella MJ, Gossain VV, Jones J. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients. J Med 1999;30(5–6):305–20.


  24. Huang YH, Wang HT, Zhu QZ, et al. Combination therapy with losartan and fosinopril for early diabetic nephropathy Di Yi Jun Yi Da Xue Xue Bao 2003;23(9):963–5.


  25. Zannad F, Kessler M, Grunfeld JP, et al. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol 2002;16(5):353–60.


  26. Coletta AP, Cleland JG, Freemantle N, et al. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004;6(5): 673–7.


  27. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001;19(10):1871–6.


  28. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110(18):2809–16.


  29. Borghi C, Marino P, Zardini P, et al. Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am J Hypertens 1997;10(10 Pt 2):247S–254S.


  30. Sharma S, Deitchman D, Eni JS. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther 1999; 6(4):181–9.


  31. Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J 1995;16(12):1892–9.


  32. Galatius-Jensen S, Wroblewski H, Emmeluth, C et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996;32(6):1148–54.


  33. Brown EJ Jr, Chew PH, MacLean A, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. Am J Cardiol 1995;75 (8):596–600.


  34. Edwards C, Blowers DA, Pover GM. Fosinopril national survey: a post-marketing surveillance study of fosinopril (Staril) in general practice in the UK. Int J Clin Pract 1997;51(6):394–8.


  35. Chang NC, Shih CM, Bi WF, et al. Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovasc Drugs Ther 2002;16(2): 141–7.


  36. Robles NR, Angulo E, Grois J, et al. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 2004;26(4):399–404.





Бионика Медиа